Nimbus Therapeutics will present two poster presentations at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO) on February 20, 2026, in Stockholm, Sweden1
The company has developed first-in-class, highly selective SIK2 inhibitors with greater than 300-fold selectivity over SIK1 and SIK312
Selective SIK2 inhibition demonstrates a dual mechanism of suppressing pro-inflammatory cytokines (TNFα, IL-23, IL-1β, CCL3, CXCL10) and promoting mucosal healing factors including IL-10, mucin-2, and occludin124
In human ex vivo models of ulcerative colitis, SIK2 inhibitors matched or surpassed upadacitinib in reducing TNFα and CCL3 secretion2
Preclinical data from anti-CD40 and dextran sodium sulfate (DSS)-induced colitis mouse models confirmed attenuation of intestinal inflammation and upregulation of mucosal healing pathways4
The SIK2 inhibitor program is advancing toward first-in-human studies for inflammatory and autoimmune diseases13
SIK2 is uniquely positioned to avoid potential toxicities associated with inhibiting other SIK isoforms, including cardiovascular effects from SIK1 inhibition and bone defects from SIK3 inhibition1
Sources:
1. https://www.biospace.com/press-releases/nimbus-therapeutics-to-present-preclinical-and-translational-data-on-novel-sik2-inhibitors-at-21st-congress-of-european-crohns-and-colitis-organisation-ecco
2. https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.337/8432449
3. https://www.nimbustx.com/2026/01/
4. https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.296/8432859